MANBA: A Potential Drug Target for Neurodegenerative Disorders

Target Name: MANBA

NCBI ID: G4126

MANBA

MANBA: A Potential Drug Target for Neurodegenerative Disorders

MANBA (Lysosomal beta A mannosidase) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and liver. It is a key player in the regulation of lysosomal sorting, which is the process by which organelles within cells are sorted and delivered to their final destinations for degradation. Mammalian brain lysosomes are a common example of organelles that are sorted and delivered to their final destinations through a process called endocytosis.

The function of MANBA is to regulate the delivery of organelles to the lysosome, and to ensure that they are properly degraded when they reach the lysosome. This is an important process for maintaining the integrity and function of the endosomal system, which is responsible for the delivery of damaged or dysfunctional organelles to the lysosome for degradation.

Research has identified MANBA as a potential drug target in the treatment of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. The reason for this is that MANBA is involved in the regulation of lysosomal function and is thought to play a role in the pathogenesis of many diseases.

One of the key benefits of targeting MANBA is that it can potentially disrupt the function of lysosomes, which is thought to contribute to the development and progression of many diseases. For example, in neurodegenerative disorders, the build-up of toxic waste products inside lysosomes is thought to contribute to the progression of the disease. By targeting MANBA, researchers may be able to reduce the production of these waste products and slow down the progression of the disease.

In addition, MANBA has also been identified as a potential biomarker for several diseases. The levels of MANBA have been found to be elevated in the brains of individuals with certain neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. This suggests that MANBA may be a useful diagnostic marker for these disorders, as well as a potential target for drug development.

Another potential mechanism by which MANBA may contribute to the development and progression of diseases is by modifying the immune response. The immune system is thought to play a critical role in the regulation of lysosomal function, and MANBA is involved in this regulation. , MANBA may be related to immune cells and immune response regulation.

In conclusion, MANBA is a protein that is expressed in various tissues throughout the body and is involved in the regulation of lysosomal sorting, which is a critical process for maintaining the integrity and function of the endosomal system. The potential drug target status of MANBA makes it an attractive target for the development of new treatments for neurodegenerative disorders, cancer, and autoimmune diseases. Furthermore, MANBA has also been identified as a potential biomarker for several diseases, which may have implications for the development of new diagnostic tests and therapies.

Protein Name: Mannosidase Beta

Functions: Exoglycosidase that cleaves the single beta-linked mannose residue from the non-reducing end of all N-linked glycoprotein oligosaccharides

The "MANBA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MANBA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets